Kymera CMO receives new option and RSU awards

Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.

Kymera Therapeutics, Inc. reported that Chief Medical Officer Terence Rooney received equity awards consisting of 76,000 stock options to buy common stock at $110.05 per share, expiring July 26, 2036, plus 38,000 restricted stock units. The RSUs vest in four equal annual installments following July 27, 2026, and the options vest 25% on July 27, 2027 with the remainder in 36 equal monthly installments, in each case subject to his continued employment.

Insider Trade Summary

Grant/Award: 114,000 shares

Grant/Award 2 txns

Insider Rooney Terence

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2	76,000	$0.00	$0.00
Grant/Award	Common Stock F1	38,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 76,000 contracts (Direct); Common Stock — 38,000 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annualinstallments following July 27, 2026, subject to the reporting person's continued employment through each vesting date.
2. F2. Twenty-five percent (25%) of the shares underlying this stock option shall vest on July 27, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

Key Figures

Stock options granted: 76,000 shares Option exercise price: $110.05 per share Option expiration date: July 26, 2036 +4 more

7 metrics

Stock options granted 76,000 shares Stock Option (Right to Buy) granted on July 27, 2026 to the CMO

Option exercise price $110.05 per share Exercise price of the 76,000 stock options granted to Terence Rooney

Option expiration date July 26, 2036 Expiration date of the granted stock options

RSUs granted 38,000 units Restricted stock units reported as an award on July 27, 2026

RSU vesting schedule 4 equal annual installments RSUs vest in four equal annual installments following July 27, 2026

Initial option vesting 25% on July 27, 2027 First vesting tranche for the 76,000 stock options

Remaining option vesting 36 equal monthly installments Balance of stock option award vests monthly after the initial 25% vesting

Key Terms

restricted stock units ("RSUs"), vesting, stock option, exercise price, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"RSUs shall vest in four equal annual installments following July 27, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

stock option financial

"shares underlying this stock option shall vest on July 27, 2027"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "110.0500" for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-07-26" for the granted stock options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kymera (KYMR) report for Chief Medical Officer Terence Rooney?

Kymera reported equity grants to CMO Terence Rooney: 76,000 stock options and 38,000 restricted stock units. These are awards, not market purchases or sales, and increase his potential future ownership if vesting and exercise conditions are met.

How many stock options were granted to Kymera (KYMR) CMO Terence Rooney and at what price?

Terence Rooney received 76,000 stock options to buy Kymera common stock at an exercise price of $110.05 per share. The options expire on July 26, 2036, subject to the detailed vesting schedule disclosed.

What RSU awards were disclosed for Kymera (KYMR) CMO Terence Rooney?

Rooney was granted 38,000 restricted stock units (RSUs), each representing a contingent right to one Kymera common share. The RSUs vest in four equal annual installments following July 27, 2026, conditioned on his continued employment through each vesting date.

What is the vesting schedule for the new Kymera (KYMR) stock options granted to Terence Rooney?

The options vest 25% on July 27, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. Vesting for each tranche requires Rooney’s continued employment through the applicable vesting date.

Were any Kymera (KYMR) shares sold in this Form 4 filing by Terence Rooney?

No sales were reported; the Form 4 shows only acquisitions via grants of stock options and RSUs. Both transactions use code A for awards, and there are no sale or disposition entries in the filing.

Are Terence Rooney’s Kymera (KYMR) equity grants tied to a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan. It characterizes these transactions as option and RSU awards rather than trades executed under a pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 06:34 PM Accepted by SEC EDGAR 07/27/2026 - 06:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rooney Terence

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A		38,000	A	$0	38,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$110.05	07/27/2026		A		76,000		(2)	07/26/2036	Common Stock	76,000	$0	76,000	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annualinstallments following July 27, 2026, subject to the reporting person's continued employment through each vesting date.

2. Twenty-five percent (25%) of the shares underlying this stock option shall vest on July 27, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)